Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Contact: | Diane L Edwards, RN,OCN, CCRP |
| Email: | diane.edwards@foa.cc |
| Phone: | 904-363-7471 |
Phase II Study of Oxaliplatin in Combination With Navelbine for the Second-Line Treatment of Advanced and Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine the response rate to treatment with oxaliplatin
and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not
been clinically evaluated yet. However, Navelbine has been safely administered with other
platinum compounds.
and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not
been clinically evaluated yet. However, Navelbine has been safely administered with other
platinum compounds.
This is a non-randomized trial for patients with previously treated Non-small cell lung
cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and
Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered
Intravenously on day 1 and day 8 every 21 days.
cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and
Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered
Intravenously on day 1 and day 8 every 21 days.
Inclusion Criteria:
- Locally advanced or metastatic non-small cell lung cancer that has recurred,
progressed, or failed to respond to previous systemic chemo.
- Measurable disease
- Good performance status (ECOG 0,1 or 2)
Exclusion Criteria:
- Previously treated with Oxaliplatin or Navelbine
- Symptomatic CNS metastases
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials